Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Adalimumab
Adalimumab
Routinely available
NICE (TA187 (SMC 417/07))
04/12/2024
Indication
Severe active crohn' s disease
Therapeutic Area
Gastro-intestinal system
Status Description
Routinely available in line with national guidance
Formulation
-
Comments
Refer to pathway or local board guidelines for preferred formulation
Link to Advice
Advice Published
19/05/2010